SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel's stock is trending following its latest earnings report, where strong Q4 results were overshadowed by weaker-than-expected Q1 guidance and acknowledged production bottlenecks. The community is sharply divided, with bears pointing to overvaluation and manufacturing challenges, while bulls emphasize Intel's strategic national security importance and long-term turnaround potential amid government backing.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as news breaks of China approving H200 chip orders, fueling speculation about accelerating demand for its next-gen Rubin architecture and solidifying its role in global AI infrastructure. The community is actively debating its market performance, with many highlighting its expanding reach into diverse sectors like AI PCs and sovereign AI factories, especially in contrast to competitors' recent struggles.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending strongly as competitor Intel's disappointing earnings outlook fuels expectations of AMD gaining significant market share. This momentum is further amplified by news of a large AI company's commitment to AMD's advanced AI chips for massive data center expansion, underscoring its pivotal role in the burgeoning AI and server markets. The community is actively discussing AMD's competitive edge and potential for new highs amidst a backdrop of anticipated CPU shortages.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune (ALT) is generating significant buzz after its MASH drug, pemvidutide, received Breakthrough Therapy Designation, signaling strong potential in a rapidly evolving market. The community is intensely discussing the drug's differentiated 'best-in-class' profile, particularly its weight loss and liver benefits, fueling widespread speculation about an imminent partnership or acquisition by a major pharmaceutical player.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is trending due to its exceptionally low public float and an ongoing strategic review that has ignited intense speculation about a potential sale or merger. Community sentiment is deeply divided, with bullish traders eyeing a significant short squeeze and highlighting the company's robust cash position, while skeptics caution about a pump-and-dump given its discontinued drug pipeline and planned operational wind-down.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. is trending following news that its merger partner, Corvex, secured a long-term NVIDIA H200 GPU deployment to support AI workloads. The community is actively discussing the stock's low float and its connection to the booming AI sector, driving conversation around significant upside potential while some also express skepticism about the news as a potential pump and dump.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as the community debates the implications of its TikTok deal, with many anticipating a significant price surge and short squeeze on news of its finalization. While some see the recent dip as a prime buying opportunity, betting on its AI infrastructure and cloud potential, others remain cautious, citing debt concerns and potential "sell the news" volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is actively discussed as its Q2 earnings report on February 3rd approaches, notably without a preceding business update. This has fueled community speculation that the company is poised to meet or exceed revenue and EPS expectations, driving strong calls for a short squeeze given its perceived undervaluation in the crucial AI infrastructure sector. Despite ongoing discussions around gross margins, many view SMCI as a pivotal player poised for significant movement.

RYVYL Inc. is a financial technology company that develops software platforms and tools that are focused on providing global payment acceptance and disbursement capabilities. It offers an innovative payment platform-as-a-service that redefines global payment solutions, enabling seamless business-to-business, consumer-to-business, and peer-to-peer transactions worldwide. The company leverages advanced electronic payment technology to deliver seamless financial solutions across global markets. It operates through two geographical segments: North America and International. The company was founded on April 10, 2007 and is headquartered in San Diego, CA.

Ryvyl Inc

Ryvyl Inc. is experiencing significant trading activity driven by its extremely low public float and high volume, sparking community discussions around a potential short squeeze. Recent filings for its merger with Roundtable, including a significant strategic partnership with The Hockey News, are fueling speculation about its future as a Web3 digital media and fintech platform. The company's ongoing efforts to maintain NASDAQ compliance are also a key focus among investors.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is generating significant buzz after its U.S. subsidiary filed a consolidated deep-sea mining application with NOAA under new, streamlined regulations, dramatically expanding its proposed commercial recovery area. The community is highly optimistic about this swift regulatory progress and the potential for strong U.S. government backing for critical mineral independence. Many bulls are dismissing recent congressional hearing criticisms as political theater, focusing instead on the company's clear path forward and anticipating further catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock following news of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">$9.1 billion acquisition</a> by French pharmaceutical giant Sanofi.The stock closed at $127.79 on Monday, up 26.1% for the day. After-hours trading showed a slight decline of 0.1% to $127.67.TD Cowen analyst Marc Frahm lowered the stock rating to ‘Hold’ from ‘Buy’ and established a price target of $130 based on the acquisition terms.&nbsp;JPMorgan reduced its rating to ‘Neutral’ from ‘Overweight’ and adjusted its target price to $129 from $130.Wolfe Research reduced Blueprint's rating to ‘Peer Perform’ from ‘Outperform’ by noting that the deal values Blueprint at $129 per share.&nbsp;Oppenheimer lowered its stock rating to ‘Perform’ from ‘Outperform,’ while describing the agreement as a “solid outcome for shareholders.”Scotiabank reduced its stock rating to ‘Sector Perform’ from ‘Outperform,’ while establishing a target price of $135.&nbsp;Wedbush assigned a $129 target after downgrading Blueprint to ‘Neutral’, while Needham downgraded it to ‘Hold.’Blueprint Medicines shareholders will receive one non-tradeable contingent value right (CVR), entitling them to two potential milestone payments of $2 and $4 per CVR, contingent on&nbsp;achieving future development and regulatory milestones for BLU-808.BLU-808 is an investigational oral inhibitor targeting wild-type KIT, which plays a role in mast cell activation involved in inflammatory diseases, including chronic urticaria.Including these potential payments, the total equity value of the Sanofi acquisition rises to approximately $9.5 billion on a fully diluted basis.Sanofi CEO Paul Hudson said this acquisition moves their rare and immunology portfolios forward.Sanofi’s earnings and gross margin will benefit from the transaction after 2026, while the company’s financial guidance for 2025 remains unaffected.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the price movement as a positive surprise, reporting a roughly 30% gain on their investment,&nbsp;noting this was better than recent returns on SpringWorks Therapeutics, but lower than several earlier buyouts this year.&nbsp;<stembedurl>https://stocktwits.com/Jackie_O_/message/616535057</stembedurl>Another user said that increased European pharma purchases of U.S. companies might be a strategy to gain favor with the Trump administration.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>Blueprint Medicines’&nbsp;stock has risen 46.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Blueprint Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Blueprint Medicines Stock  Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith

Analysts revised price targets near the deal’s $129-per-share valuation.

Equity

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines 

Shares of Blueprint Medicines Corporation (BPMC) traded 26% higher in pre-market on Monday after French pharmaceutical company Sanofi (SNY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541">announced</a> that it would acquire Blueprint in a bid to expand its rare immunological disease portfolio.Under the terms of the deal, Sanofi will pay $129 per share in cash at closing, representing an equity value of approximately $9.1 billion.The upfront purchase price represents a 27% premium to Blueprint’s closing price on Friday of $101.35.In addition, Blueprint shareholders will receive one non-tradable contingent value right (CVR), which will entitle them to receive two potential milestone payments of $2 and $4 per CVR for the achievement of future milestones for BLU-808, an investigational therapy with the potential to treat a broad range of diseases in immunology.The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis, Sanofi said. The firm added that it expects the transaction to be completed in the third quarter of 2025.The acquisition includes Ayvakit or Ayvakyt (Avapritinib), the only approved medicine for rare immunology diseases, advanced and indolent systemic mastocytosis (ASM &amp; ISM), in addition to Elenestinib, an investigational medicine for systemic mastocytosis, as well as BLU-808.Sanofi CEO Paul Hudson said that the company retains a “sizeable capacity” for further acquisitions. The firm expects the Blueprint acquisition not to have a significant impact on its financial guidance for 2025 but to be immediately accretive to gross margin and to business operating income and EPS after 2026.Last month, Sanofi said it is looking to invest at least $20 billion in the U.S. through 2030. The company also announced it would acquire U.S.-based Vigil Neuroscience, Inc. (VIGL) for about $470 million soon after.On Stocktwits, retail sentiment around Blueprint Medicines Corporation jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_06_38_AM_png_dab4b84360.webp" alt="BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, retail sentiment around Sanofi stayed unmoved within the ‘bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_14_54_AM_png_d728df50b2.webp" alt="SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="630" height="65"><figcaption>SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes U.S. pharmaceutical companies will receive acquisition offers from their European counterparts.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>While <a href="https://stocktwits.com/symbol/BPMC">BPMC stock</a> is up by about 16% this year, <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> is up by over 2%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-commits-400-million-to-boost-swiss-ai-cloud-ecosystem/chkoUr7RbHb">Microsoft Commits $400M To Boost Swiss AI, Cloud Ecosystem: Retail Mood Stays ‘Bearish’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Blueprint Medicines Corp

Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

What&#39;s the biggest driver of market volatility right now?

Stocktwits

What's the biggest driver of market volatility right now?

BPMC
Blueprint Medicines Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BPMC News

BPMCBlueprint Medicines Corp